Document Detail


Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.
MedLine Citation:
PMID:  22392043     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Obesity is associated with adverse biologic features and poor outcome in patients with invasive breast cancer, yet this relationship has not been evaluated in patients with ductal carcinoma in situ (DCIS). From 1996 to 2009, body mass index (BMI) was recorded at initial diagnosis for 1,885 patients with DCIS treated at our institution. Patients were categorized as obese (BMI ≥ 30 kg/m(2)), overweight (BMI 25 to <30 kg/m(2)), or of normal weight or underweight (BMI < 25 kg/m(2)). Logistic regression was used to examine associations between BMI and patient, clinical, and pathologic features and treatment. Local-regional recurrence was calculated using the Kaplan-Meier method. All statistical tests were two-sided. Of the 1,885 patients, 514 (27.7%) were obese, 510 (27.5%) were overweight, and 831 (44.8%) were normal/underweight. In multivariate analysis, overweight and obese patients were significantly more likely to be African American (odds ratio [OR], 3.93; 95% confidence interval [CI], 2.66-5.80) or Hispanic (OR, 1.44; CI, 1.02-2.04), be postmenopausal (OR, 1.63; CI, 1.28-2.07), have diabetes (OR, 4.60; CI, 2.60-8.12), have estrogen-receptor-positive DCIS (OR, 1.39; CI, 1.00-192), and present with a radiologic abnormality rather than clinical symptoms (OR, 1.35; CI, 1.01-1.80). At a median follow-up time of 4.96 years (range, 1.0-14.34 years), no significant differences in local recurrence rates were detected based on patients' initial BMI category. Furthermore, there was no significant difference in risk of recurrence between diabetic patients receiving metformin or not. In conclusion, higher BMI is not associated with adverse biologic features or prognosis in patients with DCIS.
Authors:
Henry M Kuerer; Sara A Lari; Banu K Arun; Chung-Yuan Hu; Abenaa Brewster; Elizabeth A Mittendorf; Constance T Albarracin; Gildy V Babiera; Abigail S Caudle; Jamie L Wagner; Jennifer K Litton; Isabelle Bedrosian; Funda Meric-Bernstam; Anthony Lucci; Kelly K Hunt
Related Documents :
17108413 - Abnormal spread of junctional acetylcholine receptor of paraspinal muscles in scoliosis...
7133743 - Stenosis and movement of the cervical spine in cervical myelopathy.
23215783 - Human serum albumin cysteinylation is increased in end stage renal disease patients and...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-03-04
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  133     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-07-03     Completed Date:  2012-11-06     Revised Date:  2013-12-12    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1131-41     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Body Mass Index*
Breast Neoplasms / complications*,  diagnosis*,  therapy
Carcinoma, Intraductal, Noninfiltrating / complications*,  diagnosis*,  therapy
Diabetes Mellitus, Type 2 / complications
Female
Humans
Middle Aged
Neoplasm Staging
Obesity / complications*
Prognosis
Recurrence
Risk Factors
Young Adult
Grant Support
ID/Acronym/Agency:
CA016672/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium eff...
Next Document:  Cross-Reactive Antibodies to Target Proteins are Dependent upon Oligomannose Glycosylated Epitopes i...